Prevention of hepatocellular carcinoma complicating chronic hepatitis C
-
Altmetric Citations
Ueno, Yoshiyuki; Sollano, Jose D; Farrell, Geoffrey
Description
Chronic hepatitis C virus (HCV) infection accounts for most cases of hepatocellular carcinoma (HCC) in Japan and is the second major cause in many other countries. Development of HCC takes a considerable time after onset of HCV infection, between 20-40 years in most cases, and usually develops after cirrhosis is established. Although only a minority of HCV infections reach this stage, the high prevalence of chronic HCV infection in many countries (1-3%) is such that HCC related to HCV infection...[Show more]
dc.contributor.author | Ueno, Yoshiyuki | |
---|---|---|
dc.contributor.author | Sollano, Jose D | |
dc.contributor.author | Farrell, Geoffrey | |
dc.date.accessioned | 2015-12-08T22:24:46Z | |
dc.identifier.issn | 0815-9319 | |
dc.identifier.uri | http://hdl.handle.net/1885/33143 | |
dc.description.abstract | Chronic hepatitis C virus (HCV) infection accounts for most cases of hepatocellular carcinoma (HCC) in Japan and is the second major cause in many other countries. Development of HCC takes a considerable time after onset of HCV infection, between 20-40 years in most cases, and usually develops after cirrhosis is established. Although only a minority of HCV infections reach this stage, the high prevalence of chronic HCV infection in many countries (1-3%) is such that HCC related to HCV infection poses a significant public health issue 20-50 years after the onset of HCV epidemics. Due to advances in testing, and accessibility of clean, disposable medical apparatus including syringes and needles, and particularly screening of donor blood for anti-HCV and by nucleic acid testing, new cases of HCV infection have decreased in most countries, except for continued transmission by injection drug users (IDU). A key difference between HBV and HCV infection is that HCV can be eradicated by effective antiviral treatment. Sustained eradication of HCV reverses hepatic fibrosis, thereby preventing progression to cirrhosis and risk of HCC. Further, it has been well demonstrated that interferon-based antiviral therapy suppresses development of HCC in high-risk patients, particularly when sustained viral response (SVR) is obtained. In summary, the two key approaches to prevent development of HCV-related HCC are primary prevention of HCV infection (adequate programs to screen donor blood, universal precautions to stop medical transmission of blood-borne viruses, curbing transmission by IDU) and potent antiviral therapy of chronic HCV infection. | |
dc.publisher | Blackwell Publishing Ltd | |
dc.source | Journal of Gastroenterology and Hepatology | |
dc.subject | Keywords: glycyrrhizic acid; iodinated poppyseed oil; iodine 131; peginterferon; ribavirin; ursodeoxycholic acid; antiviral therapy; blood donor; cancer prevention; cancer risk; chemoembolization; clinical trial; disease course; early diagnosis; eradication therapy Fibrosis; Hepatitis C virus; Hepatocellular carcinoma; Interferon; Liver cirrhosis; Risk factor; Tumor marker | |
dc.title | Prevention of hepatocellular carcinoma complicating chronic hepatitis C | |
dc.type | Journal article | |
local.description.notes | Imported from ARIES | |
local.identifier.citationvolume | 24 | |
dc.date.issued | 2009 | |
local.identifier.absfor | 110307 - Gastroenterology and Hepatology | |
local.identifier.ariespublication | u4201517xPUB99 | |
local.type.status | Published Version | |
local.contributor.affiliation | Ueno, Yoshiyuki, Tohoku University | |
local.contributor.affiliation | Sollano, Jose D, University of Santo Tomas | |
local.contributor.affiliation | Farrell, Geoffrey, College of Medicine, Biology and Environment, ANU | |
local.description.embargo | 2037-12-31 | |
local.bibliographicCitation.startpage | 531 | |
local.bibliographicCitation.lastpage | 536 | |
local.identifier.doi | 10.1111/j.1440-1746.2009.05814.x | |
dc.date.updated | 2016-02-24T10:42:17Z | |
local.identifier.scopusID | 2-s2.0-63849114866 | |
local.identifier.thomsonID | 000264735400007 | |
Collections | ANU Research Publications |
Download
File | Description | Size | Format | Image |
---|---|---|---|---|
01_Ueno_Prevention_of_hepatocellular_2009.pdf | 82.14 kB | Adobe PDF | Request a copy |
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.
Updated: 17 November 2022/ Responsible Officer: University Librarian/ Page Contact: Library Systems & Web Coordinator